20,000+ Scientists & Academics
4,000+ Scientific disciplines
20,000+ Projects posted
Trusted by 3,200+ businesses
Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss the project scope and fee and hire the expert who best meets your requirements
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but release the funds only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Contact
★★★★★
☆☆☆☆☆
USD 100 /hr
Hire Dr. Anna Grazia Recchia
Canada
USD 100 /hr

PhD, PharmD. Freelance Scientific Editor/Medical Writer with over 20+ years of experience in basic and clinical research

Profile Summary
Subject Matter Expertise
Services
Consulting Technical consulting
Product development Product feedback
Writing Grant proposal, Journal article, Review article
Research Qualitative research, Internet research, Review article, Literature search
Work Experience

Scientific and Non Scientific writer/Editor

AGReed Biomedica

July 2021 - Present

Lab manager, Research scientist

Fondazione Amelia Scorza/Italian Leukemia Association/Hematology Unit, Annunziata Hospital of Cosenza, Italy

May 2009 - May 2021

PostdoctoralResearcher

University of Calabria

May 2006 - May 2009

Education

BSc

University of Toronto

- Present

PhD

Università della Calabria Dipartimento di Farmacia e Scienze della Salute e della Nutrizione

- Present

PhamD (Farmacia)

Universita della Calabria

- Present

Certifications
  • Certification details not provided.
Publications
JOURNAL ARTICLE
Gentile, M., Morabito, F., Del Poeta, G., Mauro, F.R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Recchia, A.G., et al.(2020). Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study . Leukemia.
Morabito, F., Recchia, A.G., Vigna, E., Botta, C., Skafi, M., Abu-Rayyan, M., Atrash, M., Galimberti, S., Morabito, L., Al-Janazreh, H., et al.(2020). An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma . Expert Opinion on Pharmacotherapy. 21. (1). p. 29-38.
Morabito, F., Recchia, A.G., Vigna, E., Botta, C., Skafi, M., Abu-Rayyan, M., Atrash, M., Galimberti, S., Morabito, L., Al-Janazreh, H., et al.(2020). An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma . Expert Opinion on Pharmacotherapy. 21. (1). p. 29-38.
Martino, M., Gori, M., Tripepi, G., Recchia, A.G., Cimminiello, M., Provenzano, P.F., Naso, V., Ferreri, A., Moscato, T., Console, G., et al.(2020). A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant . Annals of Hematology. 99. (2). p. 331-341.
Gentile, M., Morabito, F., Del Poeta, G., Mauro, F.R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Recchia, A.G., et al.(2020). Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study . Leukemia.
Martino, M., Gori, M., Tripepi, G., Recchia, A.G., Cimminiello, M., Provenzano, P.F., Naso, V., Ferreri, A., Moscato, T., Console, G., et al.(2020). A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant . Annals of Hematology. 99. (2). p. 331-341.
Martino, M., Gori, M., Moscato, T., Naso, V., Ferreri, A., Provenzano, F., Loteta, B., Sanguedolce, M.C., Console, G., Dattola, A., et al.(2019). Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34<sup>+</sup> Cell and Platelet Counts . Biology of Blood and Marrow Transplantation. 25. (8). p. 1586-1591.
Morabito, F., Skafi, M., Recchia, A.G., Kashkeesh, A., Hindiyeh, M., Sabatleen, A., Morabito, L., Alijanazreh, H., Hamamreh, Y., Gentile, M.(2019). Lenalidomide for the treatment of mantle cell lymphoma . Expert Opinion on Pharmacotherapy. 20. (5). p. 487-494.
Martino, M., Ferreri, A., Naso, V., Moscato, T., Loteta, B., Gentile, M., Morabito, A., Provenzano, F., Cimminiello, M., Carella, A.M., et al.(2019). The use of ibrutinib before and after allogeneic stem cell transplantation . Expert Opinion on Orphan Drugs. 7. (4). p. 171-180.
Martino, M., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P.F., et al.(2019). Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials . Expert Review of Hematology. 12. (8). p. 665-684.
Martino, M., Ferreri, A., Naso, V., Moscato, T., Loteta, B., Gentile, M., Morabito, A., Provenzano, F., Cimminiello, M., Carella, A.M., et al.(2019). The use of ibrutinib before and after allogeneic stem cell transplantation . Expert Opinion on Orphan Drugs. 7. (4). p. 171-180.
Martino, M., Gori, M., Moscato, T., Naso, V., Ferreri, A., Provenzano, F., Loteta, B., Sanguedolce, M.C., Console, G., Dattola, A., et al.(2019). Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34<sup>+</sup> Cell and Platelet Counts . Biology of Blood and Marrow Transplantation. 25. (8). p. 1586-1591.
Morabito, F., Skafi, M., Recchia, A.G., Kashkeesh, A., Hindiyeh, M., Sabatleen, A., Morabito, L., Alijanazreh, H., Hamamreh, Y., Gentile, M.(2019). Lenalidomide for the treatment of mantle cell lymphoma . Expert Opinion on Pharmacotherapy. 20. (5). p. 487-494.
Martino, M., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P.F., et al.(2019). Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials . Expert Review of Hematology. 12. (8). p. 665-684.
Gentile, M., Shanafelt, T.D., Mauro, F.R., Laurenti, L., Rossi, D., Molica, S., Vincelli, I., Cutrona, G., Uccello, G., Pepe, S., et al.(2018). Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases . American Journal of Hematology. 93. (2). p. E35-E37.
Gentile, M., Shanafelt, T.D., Reda, G., Mauro, F.R., Zirlik, K., Ciolli, S., Laurenti, L., Del Principe, M.I., Rossi, D., Di Renzo, N., et al.(2018). Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab . Leukemia. 32. (8). p. 1869-1873.
Cutrona, G., Tripodo, C., Matis, S., Recchia, A.G., Massucco, C., Fabbi, M., Colombo, M., Emionite, L., Sangaletti, S., Gulino, A., et al.(2018). Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence . Science Translational Medicine. 10. (428).
Cutrona, G., Tripodo, C., Matis, S., Recchia, A.G., Massucco, C., Fabbi, M., Colombo, M., Emionite, L., Sangaletti, S., Gulino, A., et al.(2018). Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence . Science Translational Medicine. 10. (428).
Vigna, E., Petrungaro, A., Perri, A., Terzi, D., Recchia, A.G., Mendicino, F., La Russa, A., Bossio, S., De Stefano, L., Zinno, F., et al.(2018). Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies . Transfusion and Apheresis Science. 57. (2). p. 247-249.
Vigna, E., Petrungaro, A., Perri, A., Terzi, D., Recchia, A.G., Mendicino, F., La Russa, A., Bossio, S., De Stefano, L., Zinno, F., et al.(2018). Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies . Transfusion and Apheresis Science. 57. (2). p. 247-249.
Morabito, F., Shanafelt, T.D., Gentile, M., Reda, G., Mauro, F.R., Rossi, D., Di Renzo, N., Molica, S., Angrilli, F., Chiarenza, A., et al.(2018). Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases . American Journal of Hematology. 93. (9). p. E216-E219.
Morabito, F., Shanafelt, T.D., Gentile, M., Reda, G., Mauro, F.R., Rossi, D., Di Renzo, N., Molica, S., Angrilli, F., Chiarenza, A., et al.(2018). Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases . American Journal of Hematology. 93. (9). p. E216-E219.
Gentile, M., Shanafelt, T.D., Mauro, F.R., Laurenti, L., Rossi, D., Molica, S., Vincelli, I., Cutrona, G., Uccello, G., Pepe, S., et al.(2018). Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases . American Journal of Hematology. 93. (2). p. E35-E37.
Gentile, M., Shanafelt, T.D., Reda, G., Mauro, F.R., Zirlik, K., Ciolli, S., Laurenti, L., Del Principe, M.I., Rossi, D., Di Renzo, N., et al.(2018). Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab . Leukemia. 32. (8). p. 1869-1873.
Gentile, M., Shanafelt, T.D., Mauro, F.R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M.I., Cutrona, G., Angeletti, I., Coscia, M., et al.(2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment . European Journal of Haematology. 101. (5). p. 703-706.
Gentile, M., Shanafelt, T.D., Mauro, F.R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M.I., Cutrona, G., Angeletti, I., Coscia, M., et al.(2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment . European Journal of Haematology. 101. (5). p. 703-706.
Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Teresa Petrucci, M., Gay, F., Larocca, A., Uccello, G., Petrungaro, A., et al.(2017). Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials . American Journal of Hematology. 92. (3). p. 244-250.
Martino, M., Gori, M., Pitino, A., Gentile, M., Dattola, A., Pontari, A., Vigna, E., Moscato, T., Recchia, A.G., Barilla, S., et al.(2017). Basal CD34<sup>+</sup> Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study . Biology of Blood and Marrow Transplantation. 23. (7). p. 1215-1220.
Cutrona, G., Matis, S., Colombo, M., Massucco, C., Baio, G., Valdora, F., Emionite, L., Fabris, S., Recchia, A.G., Gentile, M., et al.(2017). Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy . Leukemia. 31. (9). p. 1894-1904.
Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Teresa Petrucci, M., Gay, F., Larocca, A., Uccello, G., Petrungaro, A., et al.(2017). Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials . American Journal of Hematology. 92. (3). p. 244-250.
Vigna, E., Martino, B., Bacci, F., Recchia, A.G., Mendicino, F., Morelli, R., Mauro, F.R., Musolino, C., Greco, R., Lucia, E., et al.(2017). Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib . Chemotherapy. 62. (6). p. 350-352.
Martino, M., Gori, M., Pitino, A., Gentile, M., Dattola, A., Pontari, A., Vigna, E., Moscato, T., Recchia, A.G., Barilla, S., et al.(2017). Basal CD34<sup>+</sup> Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study . Biology of Blood and Marrow Transplantation. 23. (7). p. 1215-1220.
Cutrona, G., Matis, S., Colombo, M., Massucco, C., Baio, G., Valdora, F., Emionite, L., Fabris, S., Recchia, A.G., Gentile, M., et al.(2017). Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy . Leukemia. 31. (9). p. 1894-1904.
Martino, M., Recchia, A.G., Console, G., Gentile, M., Cimminiello, M., Gallo, G.A., Ferreri, A., Naso, V., Irrera, G., Messina, G., et al.(2017). Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma? . Expert Opinion on Orphan Drugs. 5. (11). p. 875-887.
Petrungaro, A., Gentile, M., Mazzone, C., Greco, R., Uccello, G., Recchia, A.G., De Stefano, L., Bossio, S., Palummo, A., Morelli, R., et al.(2017). Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant . Chemotherapy. 62. (6). p. 353-356.
Vigna, E., Martino, B., Bacci, F., Recchia, A.G., Mendicino, F., Morelli, R., Mauro, F.R., Musolino, C., Greco, R., Lucia, E., et al.(2017). Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib . Chemotherapy. 62. (6). p. 350-352.
Gentile, M., Petrungaro, A., Uccello, G., Vigna, E., Recchia, A.G., Caruso, N., Bossio, S., De Stefano, L., Palummo, A., Storino, F., et al.(2017). Venetoclax for the treatment of chronic lymphocytic leukemia . Expert Opinion on Investigational Drugs. 26. (11). p. 1307-1316.
Uccello, G., Petrungaro, A., Mazzone, C., Recchia, A.G., Greco, R., Mendicino, F., Lucia, E., Vigna, E., Morabito, F., Gentile, M.(2017). Pomalidomide in multiple myeloma . Expert Opinion on Pharmacotherapy. 18. (2). p. 133-137.
Martino, M., Recchia, A.G., Console, G., Gentile, M., Cimminiello, M., Gallo, G.A., Ferreri, A., Naso, V., Irrera, G., Messina, G., et al.(2017). Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma? . Expert Opinion on Orphan Drugs. 5. (11). p. 875-887.
Gentile, M., Petrungaro, A., Uccello, G., Vigna, E., Recchia, A.G., Caruso, N., Bossio, S., De Stefano, L., Palummo, A., Storino, F., et al.(2017). Venetoclax for the treatment of chronic lymphocytic leukemia . Expert Opinion on Investigational Drugs. 26. (11). p. 1307-1316.
Petrungaro, A., Gentile, M., Mazzone, C., Greco, R., Uccello, G., Recchia, A.G., De Stefano, L., Bossio, S., Palummo, A., Morelli, R., et al.(2017). Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant . Chemotherapy. 62. (6). p. 353-356.
Gentile, M., Shanafelt, T.D., Cutrona, G., Molica, S., Tripepi, G., Alvarez, I., Mauro, F.R., Di Renzo, N., Di Raimondo, F., Vincelli, I., et al.(2016). A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients . Leukemia. 30. (6). p. 1440-1443.
Morabito, F., Voso, M.T., Hohaus, S., Gentile, M., Vigna, E., Recchia, A.G., Iovino, L., Benedetti, E., Lo-Coco, F., Galimberti, S.(2016). Panobinostat for the treatment of acute myelogenous leukemia . Expert Opinion on Investigational Drugs. 25. (9). p. 1117-1131.
Molica, S., Shanafelt, T.D., Giannarelli, D., Gentile, M., Mirabelli, R., Cutrona, G., Levato, L., Di Renzo, N., Di Raimondo, F., Musolino, C., et al.(2016). The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients . American Journal of Hematology. 91. (11). p. 1090-1095.
Ronchetti, D., Manzoni, M., Agnelli, L., Vinci, C., Fabris, S., Cutrona, G., Matis, S., Colombo, M., Galletti, S., Taiana, E., et al.(2016). LncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome . Blood Cancer Journal. 6. (9).
Vigna, E., Gentile, M., Giagnuolo, G., Recchia, A.G., Bossio, S., De Stefano, L., Morelli, R., Morabito, F.(2016). Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation . Leukemia and Lymphoma. 57. (10). p. 2445-2447.
Valdora, F., Cutrona, G., Matis, S., Morabito, F., Massucco, C., Emionite, L., Boccardo, S., Basso, L., Recchia, A.G., Salvi, S., et al.(2016). A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) . Clinical Immunology. 172. p. 52-60.
Martino, M., Tripepi, G., Messina, G., Vincelli, I.D., Console, G., Recchia, A.G., Gentile, M., Molica, S., Morabito, F.(2016). A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy . Bone Marrow Transplantation. 51. (9). p. 1197-1203.
Gentile, M., Martino, M., Recchia, A.G., Vigna, E., Morabito, L., Morabito, F.(2016). Sorafenib for the treatment of multiple myeloma . Expert Opinion on Investigational Drugs. 25. (6). p. 743-749.
Martino, M., Recchia, A.G., Fedele, R., Neri, S., Vincelli, I.D., Moscato, T., Gentile, M., Morabito, F.(2016). The role of tandem stem cell transplantation for multiple myeloma patients . Expert Opinion on Biological Therapy. 16. (4). p. 515-534.
Gentile, M., Shanafelt, T.D., Rossi, D., Laurenti, L., Mauro, F.R., Molica, S., Cutrona, G., Uccello, G., Campanelli, M., Vigna, E., et al.(2016). Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients . Blood. 128. (16). p. 2093-2095.
Gentile, M., Vigna, E., Recchia, A.G., Morabito, L., Mendicino, F., Giagnuolo, G., Morabito, F.(2015). Bendamustine in multiple myeloma . European Journal of Haematology. 95. (5). p. 377-388.
Recchia, A.G., Caruso, N., Bossio, S., Pellican&#242;, M., De Stefano, L., Franzese, S., Palummo, A., Abbadessa, V., Lucia, E., Gentile, M., et al.(2015). Flow cytometric immunobead assay for detection of BCR-ABL1 fusion proteins in chronic myleoid leukemia: Comparison with FISH and PCR techniques . PLoS ONE. 10. (6).
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A.G., Morabito, L., Morabito, F., Gentili, S.(2015). Ixazomib for the treatment of multiple myeloma . Expert Opinion on Investigational Drugs. 24. (9). p. 1287-1298.
Martino, M., Bonizzoni, E., Moscato, T., Recchia, A.G., Fedele, R., Gallo, G.A., Console, G., Messina, G., Morabito, F.(2015). Mobilization of hematopoietic stem cells with lenograstim in healthy donors: Efficacy and safety analysis according to donor age . Biology of Blood and Marrow Transplantation. 21. (5). p. 881-888.
Martino, M., Recchia, A.G., Moscato, T., Fedele, R., Neri, S., Gentile, M., Alati, C., Vincelli, I.D., Piro, E., Penna, G., et al.(2015). Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients . Cytotherapy. 17. (10). p. 1485-1493.
Fedele, R., Martino, M., Recchia, A.G., Irrera, G., Gentile, M., Morabito, F.(2015). Clinical options in relapsed or refractory hodgkin lymphoma: An updated review . Journal of Immunology Research. 2015.
Morabito, F., Recchia, A.G., Vigna, E., De Stefano, L., Bossio, S., Morabito, L., Pellican&#242;, M., Palummo, A., Storino, F., Caruso, N., et al.(2015). Promising therapies for the treatment of chronic lymphocytic leukemia . Expert Opinion on Investigational Drugs. 24. (6). p. 795-807.
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A.G., Morabito, L., Martino, M., Morabito, F., Gentili, S.(2015). Smoldering multiple myeloma: To treat or not to treat . Expert Opinion on Pharmacotherapy. 16. (6). p. 785-790.
Maura, F., Mosca, L., Fabris, S., Cutrona, G., Matis, S., Lionetti, M., Agnelli, L., Barbieri, M., D&#39;Anca, M., Manzoni, M., et al.(2015). Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia . PLoS ONE. 10. (3).
Morabito, F., Cutrona, G., Gentile, M., Fabris, S., Matis, S., Vigna, E., Todoerti, K., Colombo, M., Recchia, A.G., Bossio, S., et al.(2015). Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study . British Journal of Haematology. 168. (3). p. 455-459.
Morabito, F., Cutrona, G., Mosca, L., D&#39;Anca, M., Matis, S., Gentile, M., Vigna, E., Colombo, M., Recchia, A.G., Bossio, S., et al.(2015). Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment . Leukemia Research. 39. (8). p. 840-845.
Maura, F., Cutrona, G., Mosca, L., Matis, S., Lionetti, M., Fabris, S., Agnelli, L., Colombo, M., Massucco, C., Ferracin, M., et al.(2015). Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia . Leukemia and Lymphoma. 56. (11). p. 3150-3158.
Negrini, M., Cutrona, G., Bassi, C., Fabris, S., Zagatti, B., Colombo, M., Ferracin, M., D&#39;Abundo, L., Saccenti, E., Matis, S., et al.(2014). MicroRNAome expression in chronic lymphocytic leukemia: Comparison with normal B-cell subsets and correlations with prognostic and clinical parameters . Clinical Cancer Research. 20. (15). p. 4141-4153.
Ronchetti, D., Tuana, G., Rinaldi, A., Agnelli, L., Cutrona, G., Mosca, L., Fabris, S., Matis, S., Colombo, M., Gentile, M., et al.(2014). Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia . Genes Chromosomes and Cancer. 53. (3). p. 264-273.
Rossi, M., Gentile, M., Toscano, R., Recchia, A.G., Bossio, S., Caruso, N., De Stefano, L., Granata, T., Pellican&#242;, M., Vigna, E., et al.(2014). Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia . Leukemia and Lymphoma. 55. (6). p. 1394-1396.
Vigna, E., Recchia, A.G., Cuzzola, M., Morabito, L., Gentile, M., Morabito, F.(2014). Erythroid but not cytogenetic response in a case with 5q- syndrome: A delayed effect of lenalidomide or a consequence of deferasirox treatment? . Leukemia and Lymphoma. 55. (6). p. 1408-1409.
Gentile, M., Guido, M., Lucia, E., Vigna, E., Mazzone, C., Recchia, A.G., Morabito, F.(2014). Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib . Leukemia and Lymphoma. 55. (3). p. 709-710.
Gentile, M., Mauro, F.R., Rossi, D., Vincelli, I., Tripepi, G., Recchia, A.G., De Stefano, L., Campanelli, M., Giannarelli, D., Bossio, S., et al.(2014). Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: Analysis of 1502 cases . British Journal of Haematology. 167. (2). p. 224-232.
Gentile, M., Vigna, E., Recchia, A.G., Morabito, L., Martino, M., Morabito, F.(2014). Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients . Expert Opinion on Pharmacotherapy. 15. (10). p. 1315-1320.
Lionetti, M., Fabris, S., Cutrona, G., Agnelli, L., Ciardullo, C., Matis, S., Ciceri, G., Colombo, M., Maura, F., Mosca, L., et al.(2014). High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: Biological and clinical implications . British Journal of Haematology. 165. (5). p. 629-639.
Hoxha, M., Fabris, S., Agnelli, L., Bollati, V., Cutrona, G., Matis, S., Recchia, A.G., Gentile, M., Cortelezzi, A., Morabito, F., et al.(2014). Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia . Genes Chromosomes and Cancer. 53. (7). p. 612-621.
Martino, M., Recchia, A.G., Gentile, M., Morabito, L., Vigna, E., Cuzzola, M., Morabito, F.(2013). Diagnostic approaches for identifying acute graft-versus-host disease: What comes next? . Immunotherapy. 5. (6). p. 553-556.
Fabris, S., Mosca, L., Cutrona, G., Lionetti, M., Agnelli, L., Ciceri, G., Barbieri, M., Maura, F., Matis, S., Colombo, M., et al.(2013). Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia . American Journal of Hematology. 88. (1). p. 24-31.
Ronchetti, D., Mosca, L., Cutrona, G., Tuana, G., Gentile, M., Fabris, S., Agnelli, L., Ciceri, G., Matis, S., Massucco, C., et al.(2013). Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia . BMC Medical Genomics. 6. (1).
Gentile, M., Cutrona, G., Fabris, S., Pesce, E.A., Baldini, L., Di Raimondo, F., Musolino, C., Di Tonno, P., Di Renzo, N., Molica, S., et al.(2013). Total body computed tomography scan in the initial work-up of Binet stage a chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study . American Journal of Hematology. 88. (7). p. 539-544.
Gentile, M., Recchia, A.G., Mazzone, C., Lucia, E., Vigna, E., Morabito, F.(2013). Perspectives in the treatment of multiple myeloma . Expert Opinion on Biological Therapy. 13. (SUPPL.1).
Gentile, M., Recchia, A.G., Mazzone, C., Vigna, E., Martino, M., Morabito, L., Lucia, E., Bossio, S., De Stefano, L., Granata, T., et al.(2013). An old drug with a new future: Bendamustine in multiple myeloma . Expert Opinion on Pharmacotherapy. 14. (16). p. 2263-2280.
Morabito, F., Mosca, L., Cutrona, G., Agnelli, L., Tuana, G., Ferracin, M., Zagatti, B., Lionetti, M., Fabris, S., Maura, F., et al.(2013). Clinical monoclonal B lymphocytosis versus rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features . Clinical Cancer Research. 19. (21). p. 5890-5900.
Cuzzola, M., Fiasch&#233;, M., Iacopino, P., Messina, G., Martino, M., Console, G., Fedele, R., Massi, D., Recchia, A.G., Irrera, G., et al.(2012). A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease . Haematologica. 97. (10). p. 1532-1538.
Gentile, M., Recchia, A.G., Mazzone, C., Morabito, F.(2012). Emerging biological insights and novel treatment strategies in multiple myeloma . Expert Opinion on Emerging Drugs. 17. (3). p. 407-438.
Martino, M., Fedele, R., Massara, E., Recchia, A.G., Irrera, G., Morabito, F.(2012). Long-term safety of granulocyte colony-stimulating factor in normal donors: Is it all clear? . Expert Opinion on Biological Therapy. 12. (5). p. 609-621.
Bruno, S., Ghiotto, F., Tenca, C., Mazzarello, A.N., Bono, M., Luzzi, P., Casciaro, S., Recchia, A., Decensi, A., Morabito, F., et al.(2012). N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity . Leukemia. 26. (10). p. 2260-2268.
Morabito, F., Recchia, A.G., Mazzone, C., Gentile, M.(2012). Targeted therapy of multiple myeloma: The changing paradigm at the beginning of the new millennium . Current Cancer Drug Targets. 12. (7). p. 743-756.
Recchia, A.G., De Francesco, E.M., Vivacqua, A., Sisci, D., Panno, M.L., Ando, S., Maggiolini, M.(2011). The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1α (HIF-1α) in breast cancer cells and cardiomyocytes . Journal of Biological Chemistry. 286. (12). p. 10773-10782.
Vigna, E., Recchia, A.G., Madeo, A., Gentile, M., Bossio, S., Mazzone, C., Lucia, E., Morabito, L., Gigliotti, V., Stefano, L.D., et al.(2011). Epigenetic regulation in myelodysplastic syndromes: Implications for therapy . Expert Opinion on Investigational Drugs. 20. (4). p. 465-493.
Lappano, R., Recchia, A.G., de Francesco, E.M., Angelone, T., Cerra, M.C., Picard, D., Maggiolini, M.(2011). The cholesterol metabolite 25-Hydroxycholesterol activates estrogen receptor α-Mediated signaling in cancer cells and in cardiomyocytes . PLoS ONE. 6. (1).
Maura, F., Cutrona, G., Fabris, S., Colombo, M., Tuana, G., Agnelli, L., Matis, S., Lionetti, M., Gentile, M., Recchia, A.G., et al.(2011). Relevance of stereotyped b-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia . PLoS ONE. 6. (8).
Morabito, F., De Filippi, R., Laurenti, L., Zirlik, K., Recchia, A.G., Gentile, M., Morelli, E., Vigna, E., Gigliotti, V., Calemma, R., et al.(2011). The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia . Blood. 118. (24). p. 6353-6361.
Lappano, R., Recchia, A.G., de Francesco, E.M., Angelone, T., Cerra, M.C., Picard, D., Maggiolini, M.(2011). The cholesterol metabolite 25-Hydroxycholesterol activates estrogen receptor α-Mediated signaling in cancer cells and in cardiomyocytes . PLoS ONE. 6. (1).
Fabris, S., Bollati, V., Agnelli, L., Morabito, F., Motta, V., Cutrona, G., Matis, S., Recchia, A.G., Gigliotti, V., Gentile, M., et al.(2011). Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia . Epigenetics. 6. (2). p. 188-194.
Recchia, A.G., De Francesco, E.M., Vivacqua, A., Sisci, D., Panno, M.L., Ando, S., Maggiolini, M.(2011). The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1α (HIF-1α) in breast cancer cells and cardiomyocytes . Journal of Biological Chemistry. 286. (12). p. 10773-10782.
Lucia, E., Recchia, A.G., Gentile, M., Bossio, S., Vigna, E., Mazzone, C., Madeo, A., Morabito, L., Gigliotti, V., Stefano, L.D., et al.(2011). Janus kinase 2 inhibitors in myeloproliferative disorders . Expert Opinion on Investigational Drugs. 20. (1). p. 41-59.
Gentile, M., Recchia, A.G., Vigna, E., Mazzone, C., Lucia, E., Gigliotti, V., Bossio, S., Madeo, A., Morabito, L., Servillo, P., et al.(2011). Lenalidomide in the treatment of chronic lymphocytic leukemia . Expert Opinion on Investigational Drugs. 20. (2). p. 273-286.
Fabris, S., Scarciolla, O., Morabito, F., Cifarelli, R.A., Dininno, C., Cutrona, G., Matis, S., Recchia, A.G., Gentile, M., Ciceri, G., et al.(2011). Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: A comparative study . Genes Chromosomes and Cancer. 50. (9). p. 726-734.
Morabito, F., Gentile, M., Mazzone, C., Bringhen, S., Vigna, E., Lucia, E., Recchia, A.G., Raimondo, F.D., Musto, P., Palumbo, A.(2010). Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs . European Journal of Haematology. 85. (3). p. 181-191.
Vigna, E., De Vivo, A., Gentile, M., Morelli, R., Lucia, E., Mazzone, C., Recchia, A.G., Vianelli, N., Morabito, F.(2010). Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients . Transplant Infectious Disease. 12. (5). p. 428-431.
Morabito, F., Cutrona, G., Gentile, M., Loiacono, F., Matis, S., Recchia, A.G., Gigliotti, V., Callea, V., Zupo, S., Ferrarini, M.(2010). More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia . Leukemia Research. 34. (12).
Recchia, A.G., Filice, E., Pellegrino, D., Dobrina, A., Cerra, M.C., Maggiolini, M.(2009). Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes . Journal of Molecular and Cellular Cardiology. 46. (3). p. 352-359.
Recchia, A.G., Filice, E., Pellegrino, D., Dobrina, A., Cerra, M.C., Maggiolini, M.(2009). Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes . Journal of Molecular and Cellular Cardiology. 46. (3). p. 352-359.
Filice, E., Recchia, A.G., Pellegrino, D., Angelone, T., Maggiolini, M., Cerra, M.C.(2009). A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat . Journal of Physiology and Pharmacology. 60. (4). p. 3-10.
Filice, E., Recchia, A.G., Pellegrino, D., Angelone, T., Maggiolini, M., Cerra, M.C.(2009). A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat . Journal of Physiology and Pharmacology. 60. (4). p. 3-10.
Recchia, A.G., Musti, A.M., Lanzino, M., Panno, M.L., Turano, E., Zumpano, R., Belfiore, A., And&#242;, S., Maggiolini, M.(2009). A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells . International Journal of Biochemistry and Cell Biology. 41. (3). p. 603-614.
Recchia, A.G., Musti, A.M., Lanzino, M., Panno, M.L., Turano, E., Zumpano, R., Belfiore, A., And&#242;, S., Maggiolini, M.(2009). A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells . International Journal of Biochemistry and Cell Biology. 41. (3). p. 603-614.
Angelone, T., Filice, E., Quintieri, A.M., Imbrogno, S., Recchia, A., Puler&#224;, E., Mannarino, C., Pellegrino, D., Cerra, M.C.(2008). β<inf>3</inf>-Adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway . Acta Physiologica. 193. (3). p. 229-239.
Angelone, T., Filice, E., Quintieri, A.M., Imbrogno, S., Recchia, A., Puler&#224;, E., Mannarino, C., Pellegrino, D., Cerra, M.C.(2008). β<inf>3</inf>-Adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway . Acta Physiologica. 193. (3). p. 229-239.
Vivacqua, A., Bonofiglio, D., Recchia, A.G., Musti, A.M., Picard, D., And&#242;, S., Maggiolini, M.(2006). The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells . Molecular Endocrinology. 20. (3). p. 631-646.
Vivacqua, A., Bonofiglio, D., Recchia, A.G., Musti, A.M., Picard, D., And&#242;, S., Maggiolini, M.(2006). The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells . Molecular Endocrinology. 20. (3). p. 631-646.
Montanaro, D., Maggiolini, M., Recchia, A.G., Sirianni, R., Aquila, S., Barzon, L., Fallo, F., And&#242;, S., Pezzi, V.(2005). Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation . Journal of Molecular Endocrinology. 35. (2). p. 245-256.
Maggiolini, M., Recchia, A.G., Bonofiglio, D., Catalano, S., Vivacqua, A., Carpino, A., Rago, V., Rossi, R., And&#242;, S.(2005). The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor α in human breast cancer cells . Journal of Molecular Endocrinology. 35. (2). p. 269-281.
Maggiolini, M., Recchia, A.G., Bonofiglio, D., Catalano, S., Vivacqua, A., Carpino, A., Rago, V., Rossi, R., And&#242;, S.(2005). The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor α in human breast cancer cells . Journal of Molecular Endocrinology. 35. (2). p. 269-281.
Montanaro, D., Maggiolini, M., Recchia, A.G., Sirianni, R., Aquila, S., Barzon, L., Fallo, F., And&#242;, S., Pezzi, V.(2005). Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation . Journal of Molecular Endocrinology. 35. (2). p. 245-256.
Maggiolini, M., Recchia, A.G., Carpino, A., Vivacqua, A., Fasanella, G., Rago, V., Pezzi, V., Briand, P.-A., Picard, D., And&#242;, S.(2004). Oestrogen receptor β is required for androgen-stimulated proliferation of LNCaP prostate cancer cells . Journal of Molecular Endocrinology. 32. (3). p. 777-791.
Recchia, A.G., Vivacqua, A., Gabriele, S., Carpino, A., Fasanella, G., Rago, V., Bonofiglio, D., Maggiolini, M.(2004). Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor α . Food Additives and Contaminants. 21. (2). p. 134-144.
Recchia, A.G., Vivacqua, A., Gabriele, S., Carpino, A., Fasanella, G., Rago, V., Bonofiglio, D., Maggiolini, M.(2004). Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor α . Food Additives and Contaminants. 21. (2). p. 134-144.
Maggiolini, M., Recchia, A.G., Carpino, A., Vivacqua, A., Fasanella, G., Rago, V., Pezzi, V., Briand, P.-A., Picard, D., And&#242;, S.(2004). Oestrogen receptor β is required for androgen-stimulated proliferation of LNCaP prostate cancer cells . Journal of Molecular Endocrinology. 32. (3). p. 777-791.
Maggiolini, M., Vivacqua, A., Fasanella, G., Recchia, A.G., Sisci, D., Pezzi, V., Montanaro, D., Musti, A.M., Picard, D., And&#242;, S.(2004). The G protein-coupled receptor GPR30 Mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells . Journal of Biological Chemistry. 279. (26). p. 27008-27016.
Maggiolini, M., Vivacqua, A., Fasanella, G., Recchia, A.G., Sisci, D., Pezzi, V., Montanaro, D., Musti, A.M., Picard, D., And&#242;, S.(2004). The G protein-coupled receptor GPR30 Mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells . Journal of Biological Chemistry. 279. (26). p. 27008-27016.
Vivacqua, A., Recchia, A.G., Fasanella, G., Gabriele, S., Carpino, A., Rago, V., Di Gioia, M.L., Leggio, A., Bonofiglio, D., Liguori, A., et al.(2003). The Food Contaminants Bisphenol A and 4-Nonylphenol Act as Agonists for Estrogen Receptor α in MCF7 Breast Cancer Cells . Endocrine. 22. (3). p. 275-284.
Vivacqua, A., Recchia, A.G., Fasanella, G., Gabriele, S., Carpino, A., Rago, V., Di Gioia, M.L., Leggio, A., Bonofiglio, D., Liguori, A., et al.(2003). The Food Contaminants Bisphenol A and 4-Nonylphenol Act as Agonists for Estrogen Receptor α in MCF7 Breast Cancer Cells . Endocrine. 22. (3). p. 275-284.
Recchia, A.G., Shear, N.H.(1994). Organization and functioning of an adverse drug reaction clinic . Journal of Clinical Pharmacology. 34. (1). p. 68-79.
BOOK
Vigna, E., Recchia, A.G., Gentile, M., Bossio, S., Stefano, L.D., Granata, T., Caruso, N., Pellican&#242;, M.V., Franzese, S., Fortunato, M.(2013). Leishmaniases: Etiology, epidemiology and clinical hematology . Leishmaniasis: Symptoms, Treatment and Potential Complications. p. 29-50.
Gentile, M., Vigna, E., Mazzone, C., Lucia, E., Recchia, A.G., Morabito, L., Bisconte, M.G., Gentile, C., Morabito, F.(2010). Rituximab for the treatment of patients with chronic lymphocytic leukemia . Cancer Management and Research. 2. (1). p. 71-81.